ADC Therapeutics SA Current Ratio 2019-2023 | ADCT
ADC Therapeutics SA current ratio from 2019 to 2023. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| ADC Therapeutics SA Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2023-03-31 |
$0.38B |
$0.08B |
4.69 |
| 2022-12-31 |
$0.45B |
$0.10B |
4.51 |
| 2022-09-30 |
$0.44B |
$0.09B |
5.00 |
| 2022-06-30 |
$0.42B |
$0.07B |
5.76 |
| 2022-03-31 |
$0.49B |
$0.07B |
6.89 |
| 2021-12-31 |
$0.53B |
$0.07B |
7.10 |
| 2021-09-30 |
$0.57B |
$0.06B |
9.59 |
| 2021-06-30 |
$0.39B |
$0.05B |
7.66 |
| 2021-03-31 |
$0.39B |
$0.04B |
9.50 |
| 2020-12-31 |
$0.45B |
$0.04B |
11.14 |
| 2020-09-30 |
$0.51B |
$0.03B |
15.55 |
| 2020-06-30 |
$0.36B |
$0.03B |
11.45 |
| 2020-03-31 |
$0.00B |
|
0.00 |
| 2019-12-31 |
$0.00B |
|
0.00 |
| 2019-09-30 |
$0.00B |
|
0.00 |
| 2019-06-30 |
$0.00B |
|
0.00 |
| 2018-12-31 |
$0.14B |
$0.02B |
6.36 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.196B |
$0.210B |
|
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
|
